$0.05
6.65% today
Nasdaq, Sep 04, 04:47 pm CET
ISIN
US00653A1079
Symbol
ADAP

Adaptimmune Therapeutics PLC Sponsored ADR Target price 2025 - Analyst rating & recommendation

Adaptimmune Therapeutics PLC Sponsored ADR Classifications & Recommendation:

Hold
56%
Sell
44%

Adaptimmune Therapeutics PLC Sponsored ADR Price Target

Target Price $0.47
Price $0.05
Potential
Number of Estimates 5
5 Analysts have issued a price target Adaptimmune Therapeutics PLC Sponsored ADR 2026 . The average Adaptimmune Therapeutics PLC Sponsored ADR target price is $0.47. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 0 Analysts recommend Adaptimmune Therapeutics PLC Sponsored ADR to buy, 5 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Adaptimmune Therapeutics PLC Sponsored ADR stock has an average upside potential 2026 of . Most analysts recommend the Adaptimmune Therapeutics PLC Sponsored ADR stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 178.03 40.79
195.34% 77.09%
EBITDA Margin -23.13% -277.55%
88.46% 1,099.91%
Net Margin -39.77% -1,670.11%
78.94% 4,098.98%

8 Analysts have issued a sales forecast Adaptimmune Therapeutics PLC Sponsored ADR 2025 . The average Adaptimmune Therapeutics PLC Sponsored ADR sales estimate is

$40.8m
Unlock
. This is
37.33% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$56.3m 13.57%
Unlock
, the lowest is
$25.5m 60.85%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $178m 195.34%
2025
$40.8m 77.09%
Unlock
2026
$62.1m 52.35%
Unlock
2027
$119m 91.09%
Unlock
2028
$248m 108.40%
Unlock
2029
$333m 34.60%
Unlock
2030
$393m 18.11%
Unlock
2031
$404m 2.63%
Unlock
2032
$404m 0.00%
Unlock

3 Analysts have issued an Adaptimmune Therapeutics PLC Sponsored ADR EBITDA forecast 2025. The average Adaptimmune Therapeutics PLC Sponsored ADR EBITDA estimate is

$-113m
Unlock
. This is
16.03% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-117m 13.56%
Unlock
, the lowest is
$-109m 19.32%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-41.2m 65.92%
2025
$-113m 174.94%
Unlock
2026
$-56.2m 50.36%
Unlock

EBITDA Margin

2024 -23.13% 88.46%
2025
-277.55% 1,099.91%
Unlock
2026
-90.43% 67.42%
Unlock

8 Adaptimmune Therapeutics PLC Sponsored ADR Analysts have issued a net profit forecast 2025. The average Adaptimmune Therapeutics PLC Sponsored ADR net profit estimate is

$-681m
Unlock
. This is
301.33% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-618m 263.95%
Unlock
, the lowest is
$-733m 331.49%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-70.8m 37.82%
2025
$-681m 862.14%
Unlock
2026
$-414m 39.29%
Unlock
2027
$-730m 76.47%
Unlock

Net Margin

2024 -39.77% 78.94%
2025
-1,670.11% 4,098.98%
Unlock
2026
-665.56% 60.15%
Unlock
2027
-614.64% 7.65%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.05 -0.43
44.44% 760.00%
P/E negative
EV/Sales 0.37

8 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast for earnings per share. The average Adaptimmune Therapeutics PLC Sponsored ADR EPS is

$-0.43
Unlock
. This is
290.91% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.39 254.55%
Unlock
, the lowest is
$-0.46 318.18%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.05 44.44%
2025
$-0.43 760.00%
Unlock
2026
$-0.26 39.53%
Unlock
2027
$-0.46 76.92%
Unlock

P/E ratio

Current -0.48 98.12%
2025
-0.12 74.91%
Unlock
2026
-0.20 66.67%
Unlock
2027
-0.11 45.00%
Unlock

Based on analysts' sales estimates for 2025, the Adaptimmune Therapeutics PLC Sponsored ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 0.23 75.79%
2025
0.37 59.13%
Unlock
2026
0.24 34.37%
Unlock
2027
0.13 47.67%
Unlock
2028
0.06 52.03%
Unlock
2029
0.04 25.70%
Unlock
2030
0.04 15.40%
Unlock
2031
0.04 2.37%
Unlock
2032
0.04 0.00%
Unlock

P/S ratio

Current 0.24 89.75%
2025
0.38 59.56%
Unlock
2026
0.25 34.37%
Unlock
2027
0.13 47.67%
Unlock
2028
0.06 52.02%
Unlock
2029
0.05 25.69%
Unlock
2030
0.04 15.43%
Unlock
2031
0.04 2.57%
Unlock
2032
0.04 0.00%
Unlock

Current Adaptimmune Therapeutics PLC Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Jul 29 2025
Mizuho
Locked
Locked
Locked Jun 26 2025
Barclays
Locked
Locked
Locked May 14 2025
Wells Fargo
Locked
Locked
Locked May 14 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 01 2025
Guggenheim
Locked
Locked
Locked Mar 26 2025
Scotiabank
Locked
Locked
Locked Mar 21 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 29 2025
Locked
Mizuho:
Locked
Locked
Jun 26 2025
Locked
Barclays:
Locked
Locked
May 14 2025
Locked
Wells Fargo:
Locked
Locked
May 14 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 01 2025
Locked
Guggenheim:
Locked
Locked
Mar 26 2025
Locked
Scotiabank:
Locked
Locked
Mar 21 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today